[go: up one dir, main page]

AU2003232171A1 - Combined use of a modulator of cd3 and a beta cell resting compound - Google Patents

Combined use of a modulator of cd3 and a beta cell resting compound

Info

Publication number
AU2003232171A1
AU2003232171A1 AU2003232171A AU2003232171A AU2003232171A1 AU 2003232171 A1 AU2003232171 A1 AU 2003232171A1 AU 2003232171 A AU2003232171 A AU 2003232171A AU 2003232171 A AU2003232171 A AU 2003232171A AU 2003232171 A1 AU2003232171 A1 AU 2003232171A1
Authority
AU
Australia
Prior art keywords
modulator
combined use
beta cell
cell resting
resting compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003232171A
Inventor
Birgitte Koch Michelsen
Jeppe Sturis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2003232171A1 publication Critical patent/AU2003232171A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2003232171A 2002-06-14 2003-06-12 Combined use of a modulator of cd3 and a beta cell resting compound Abandoned AU2003232171A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38919002P 2002-06-14 2002-06-14
DKPA200200911 2002-06-14
DKPA200200911 2002-06-14
US60/389,190 2002-06-14
PCT/DK2003/000386 WO2003105896A1 (en) 2002-06-14 2003-06-12 Combined use of a modulator of cd3 and a beta cell resting compound

Publications (1)

Publication Number Publication Date
AU2003232171A1 true AU2003232171A1 (en) 2003-12-31

Family

ID=29737855

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003232171A Abandoned AU2003232171A1 (en) 2002-06-14 2003-06-12 Combined use of a modulator of cd3 and a beta cell resting compound

Country Status (2)

Country Link
AU (1) AU2003232171A1 (en)
WO (1) WO2003105896A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005020462D1 (en) 2004-08-25 2010-05-20 Essentialis Inc PHARMACEUTICAL FORMULATIONS OF CALIUM ATP CHANNEL OPENERS AND THEIR USES
EP1904105A4 (en) 2005-07-11 2010-02-17 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
ES2374963T3 (en) 2006-01-05 2012-02-23 Essentialis, Inc. SALES OF OPENING AGENTS OF THE ATP DEPENDENT CHANNEL OF ATP AND USES OF THE SAME.
EP2094302A4 (en) * 2006-12-21 2010-12-08 Macrogenics Inc Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
WO2020130836A1 (en) * 2018-12-21 2020-06-25 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) Compound for use in treatment and prevention of type i diabetes
NL2022291B1 (en) * 2018-12-21 2020-07-21 Academisch Ziekenhuis Leiden Compound for Use in Treatment and Prevention of Type I Diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727775B2 (en) * 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
ATE281460T1 (en) * 1996-01-17 2004-11-15 Univ Liege PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1-4-THIAZINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
IL133604A0 (en) * 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
US6147098A (en) * 1998-05-11 2000-11-14 Novo Nordisk A/S Substituted guanidines and diaminonitroethenes, their preparation and use
HUP0104646A3 (en) * 1998-12-18 2004-05-28 Novo Nordisk As Fused 1,2,4-thiadiazine derivatives, their preparation and use

Also Published As

Publication number Publication date
WO2003105896A1 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
AU2003232172A1 (en) Combined use of a modulator of cd3 and a glp-1 compound
AU2003210393A1 (en) A data integration and knowledge management solution
AU2001296497A1 (en) Workflow management software overview
AU2003231289A1 (en) Power modulator
AU2003261214A1 (en) Use of printing and other technology for micro-component placement
AU2003301372A1 (en) Mass customization for management of healthcare
AU2003221936A1 (en) Compositions comprising a dispersant and microcapsules containing an active material
AU2003298602A1 (en) Active digital hologram display
AU2003277068A1 (en) Schedule chart for project management
AU2003230834A1 (en) Antagonists of il-21 and modulation of il-21-mediated t cell responses
AU2003270312A1 (en) Capacity management and timing
AU2003292463A1 (en) A wrapping material with a z-lock system and methods of making and using the same
AU2003221173A1 (en) Placenta-origin mesenchymal cells and medicinal use thereof
AU2003223431A1 (en) Strap pack carrier
AU2003271440A1 (en) A fuel cell system and method of operating the same
AU2003230871A1 (en) Group management
AU2003287406A1 (en) Digital-rights management
WO2004013784A8 (en) Workflow management architecture
AU1171501A (en) Placement of idle periods
AU2003232171A1 (en) Combined use of a modulator of cd3 and a beta cell resting compound
AU2002951194A0 (en) Conversion of sludges and carbonaceous materials
AU2002232831A1 (en) Date cycling storage calendar
AU2003303207A1 (en) Methods and compositions for wound management
AU2003269642A1 (en) A fuel cell system and method of operating the same
AU2002307122A1 (en) A novel modulator of non-genonic activity of nuclear receptors (mnar) and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase